Considering the known interaction between CD161 and LLT1 during T cell activation [19, 24], the CD161/LLT1 combination could predict a more accurate tumor classification for OSCC biological behavior and patient stratification compared with each biomarker alone. This evidence concerns the gene CLEC2D and neoplasm.